Full-Time

Director – Aficamten Global Marketing and Commercial Strategy

Posted on 1/28/2025

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Compensation Overview

$240k - $266kAnnually

Senior, Expert

Villanova, PA, USA + 1 more

More locations: San Bruno, CA, USA

Category
General Marketing
Growth Marketing
Growth & Marketing
Required Skills
Market Research
Product Management
Marketing
Requirements
  • Bachelor’s degree in business or scientific fields.
  • MBA or Commercial Experience is preferred.
  • 10+ years of product management and marketing experience including 5+ years in strategy development.
  • Scientific background is preferred.
  • Previous leadership experience in marketing and/or business development and/or alliance management.
  • Previous regional marketing and/or sales experience preferred. Ideally with prior experience working in Asian markets.
  • Self-starter with the ability to work optimally and collaborate with cross-functional teams (e.g., Global commercial, Business Development, Local country Marketing, Regulatory, Clinical).
  • Attention to details mindset preferred.
Responsibilities
  • Act as the primary connection and key day-to-day partner between Cytokinetics and our collaborators as it relates to regional implementation of Global Commercialization Plans.
  • Review and influence partner commercialization plans to assess alignment and consistency with the Global Commercialization Plan, including product positioning, core claims, branding, promotional materials, Regional and Global Key Opinion Leader planning, HEOR Publications, and Speaker Programs.
  • Provide feedback to JCC members on commercialization plan and performance versus that plan.
  • Participate in Joint Commercialization Committee meetings (JCC) as an observer and provide content update based on key analyses.
  • Oversee commercial coordination with joint commercialization committees and ensure appropriate implementation of governance model.
  • Identify areas for improved commercial coordination between partner organizations and Cytokinetics.
  • Represent the collaboration and partners in development of global commercialization planning activities, including supply forecasts, launch timelines, and manufacturing.
  • Engage with trademark counsel and related functions to ensure appropriate implementation and trademark protection of Cytokinetics’ brands.
  • Partner with alliance management to drive scheduling formal JCC interactions and organize structured feedback to partners on regional commercialization plans.
  • Coordinate with forecast and related committees to provide appropriate supply estimates from partner organizations.
  • Prepare FAQ / background documents for CCO use in earnings calls and investor meetings.
  • Serve as internal source of market knowledge for partners’ market dynamics, including patient flows, physician market research, reimbursement environment, health care policy, etc.
  • Integrate lifecycle management opportunities into planning process that support regional partners success.
  • Serve as a conduit to facilitate decision regarding questions from licensee’s and serve as Cytokinetics representative on S&OP process relative to partner forecast where we are responsible for drug substance, drug product or Finished goods.
  • Collaborate with business development colleagues to engage potential partners for regional commercialization of our medicines.
  • Develop commercial business cases for global expansion and partnership considerations by region or country, as appropriate.
  • Participate in due diligence assessments of potential collaborators and partners to assess commercial capabilities, market expertise and alignment with Cytokinetics culture.
  • Develop strategy regarding preferred commercialization models (e.g., multiple partners, limited distributorship/partners, out-licensing, etc.).
Desired Qualifications
  • MBA or Commercial Experience is preferred.
  • Scientific background is preferred.
  • Previous regional marketing and/or sales experience preferred. Ideally with prior experience working in Asian markets.
  • Attention to details mindset preferred.

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to address the unmet medical needs of patients suffering from conditions like heart failure, ALS, and HCM, ultimately improving their quality of life.

Company Size

501-1,000

Company Stage

IPO

Headquarters

South San Francisco, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent investments indicate strong interest in muscle activators and inhibitors.
  • Strategic partnerships, like with Sanofi, expand market reach and potential revenue.
  • Significant funding from Royalty Pharma supports commercial launch and R&D advancements.

What critics are saying

  • Increased competition could impact market share and profitability.
  • Potential delays in clinical trials could hinder drug commercialization.
  • Dependence on strategic partnerships may expose Cytokinetics to risks if challenges arise.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
  • The company has a robust pipeline including omecamtiv mecarbil and aficamten.
  • Cytokinetics engages in strategic partnerships, like with Sanofi, to expand market reach.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-5%

2 year growth

-2%
Stock Titan
Jan 6th, 2025
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA.

BioSpace
Dec 20th, 2024
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

Cytokinetics announces Sanofi acquired rights to develop and commercialize Aficamten in Greater China.

MarketBeat
Nov 26th, 2024
Intech Investment Management LLC Invests $1.73 Million in Cytokinetics, Incorporated (NASDAQ:CYTK)

Intech Investment Management LLC invests $1.73 million in Cytokinetics, Incorporated (NASDAQ:CYTK).

MediaPost
Oct 11th, 2024
Cytokinetics Educates Docs On Non-Physical Ordeals Of Cardio Condition

Setting the stage for its first consumer product after 25 years as a biopharma development company, Cytokinetics has launched "HCM Beyond the Heart," an awareness campaign educating cardiologists and other healthcare professionals (HCP) about the personal burdens caused by hypertrophic cardiomyopathy (HCM), a leading cause of sudden cardiac death.

Business Directory 88
Aug 21st, 2024
Armistice Capital Performance: A Closer Look at Healthcare Investment Strategies

Armistice Capital has invested in Cytokinetics Incorporated, a late-stage biopharmaceutical organization investigating treatments for impaired muscle function-related cardiovascular and neuromuscular diseases.

INACTIVE